Krystal Biotech (NASDAQ:KRYS) EVP John Charles Thomas Sells 1,000 Shares of Stock

Krystal Biotech, Inc. (NASDAQ:KRYS) EVP John Charles Thomas sold 1,000 shares of Krystal Biotech stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $347.27, for a total transaction of $347,270.00. Following the completion of the sale, the executive vice president directly owned 1,000 shares in the company, valued at $347,270. This represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John Charles Thomas also recently made the following trade(s):

• On Tuesday, May 26th, John Charles Thomas sold 642 shares of Krystal Biotech stock. The stock was sold at an average price of $302.03, for a total value of $193,903.26.

Krystal Biotech Stock Performance

Shares of KRYS opened at $372.25 on Friday. Krystal Biotech, Inc. has a one year low of $130.50 and a one year high of $376.28. The stock has a market capitalization of $10.97 billion, a price-to-earnings ratio of 49.77 and a beta of 0.53. The stock has a 50 day moving average price of $304.72 and a 200 day moving average price of $276.69.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, May 4th. The company reported $1.83 earnings per share for the quarter, topping analysts’ consensus estimates of $1.45 by $0.38. The business had revenue of $116.36 million for the quarter, compared to analyst estimates of $112.11 million. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. On average, analysts predict that Krystal Biotech, Inc. will post 7.66 earnings per share for the current year.

Institutional Investors Weigh In On Krystal Biotech

Several hedge funds and other institutional investors have recently bought and sold shares of KRYS. Sound Income Strategies LLC increased its position in shares of Krystal Biotech by 1,270.0% during the fourth quarter. Sound Income Strategies LLC now owns 137 shares of the company’s stock worth $34,000 after purchasing an additional 127 shares in the last quarter. Western Wealth Management LLC purchased a new position in Krystal Biotech during the 1st quarter worth approximately $34,000. Greenline Wealth Management LLC acquired a new position in Krystal Biotech during the fourth quarter worth approximately $34,000. Danske Bank A S acquired a new position in Krystal Biotech during the third quarter worth approximately $35,000. Finally, UMB Bank n.a. lifted its stake in Krystal Biotech by 34.6% in the fourth quarter. UMB Bank n.a. now owns 144 shares of the company’s stock valued at $36,000 after buying an additional 37 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

KRYS has been the topic of several research analyst reports. Citigroup boosted their price objective on Krystal Biotech from $371.00 to $378.00 and gave the company a “buy” rating in a report on Tuesday, May 5th. Evercore reaffirmed an “outperform” rating and issued a $300.00 target price on shares of Krystal Biotech in a research report on Tuesday, May 5th. HC Wainwright increased their price target on shares of Krystal Biotech from $310.00 to $361.00 and gave the stock a “buy” rating in a research report on Tuesday, June 16th. Wolfe Research started coverage on shares of Krystal Biotech in a report on Friday, March 27th. They issued a “peer perform” rating for the company. Finally, Weiss Ratings raised shares of Krystal Biotech from a “buy (b-)” rating to a “buy (b)” rating in a research note on Tuesday, June 16th. Ten equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $340.56.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.